GSK has developed a new drug for lung cancer which is called Jideytro (zidesamtinib), and it has also been approved by the US FDA. This step by GSK actually brings a new treatment option for the people living with a rare type of lung cancer.
GSK’s New Lung Cancer Drug?
Zidesamtinib is a next-generation tyrosine kinase inhibitor (TKI) engineered specifically to inhibit solvent-front resistance mutations (such as G2032R) while selectively sparing TRKB to minimize neurological toxicities like dizziness.
The lung cancer drug has been developed for adults with ROS1-positive advanced or metastatic non-small cell lung cancer (NSCLC). In simple words, it is actually for the patients whose cancer has continued to grow even after treating the cancer with another ROS1-targeted medicine.
A New Treatment Option for Rare ROS1-Positive Lung Cancer
So, this is a rare lung cancer as it affects only about 1-2% of people diagnosed with NSCLC. Even though it is not that common, patients will need better treatment options when their first therapy stops working.
FDA has approved it after seeing encouraging results in the clinical studies.
Clinical Trial Results Behind Lung Cancer Drug Approval
The FDA granted approval ahead of its target PDUFA date (originally September 18, 2026), following prior Breakthrough Therapy and Orphan Drug Designations. And the approval was driven by results from the global Phase 1/2 ARROS-1 trial (NCT05118789).
In the trial, 44% of 117 patients had their tumors shrink or disappear, and among those who responded to the treatment, 82% were still responding at six months and 69% at 12 months.
The medicine also worked well in patients whose cancer had spread to the brain, which is a common challenge in advanced ROS1-positive lung cancer.
How Does the Lung Cancer Drug Jideytro Work?
The lung cancer drug works by targeting potent, ROS1-selective tyrosine kinase inhibitor (TKI), which helps cancer cells grow. And then it blocks the signals that allow these cancer cells to multiply, helping slow down or stop the disease.
This lung cancer drug was also designed to work even when older ROS1 medicines are no longer effective because of treatment resistance.
GSK’s Acquisition of Nuvalent and Cancer Research Expansion
This approval comes soon after GSK completed its $10.6 billion acquisition of Nuvalent, the biotech company that developed Jideytro.
“The rapid progression of Jideytro from development to approval reflects both the strength of the underlying science and the urgent need for additional effective and tolerable treatments for ROS1-positive lung cancer,” Chief Scientific Officer Tony Wood said in GSK’s statement.
The acquisition was one of GSK’s biggest investments in cancer research, and this FDA approval shows that the company is already making progress with the new medicine.
The Future of Targeted Cancer Therapies
Over the last few years, targeted therapies have improved treatment for many patients with specific genetic changes, but there is still a need for more effective medicines, especially for people whose cancer becomes resistant to existing treatments.
The approval of Jideytro, lung cancer drug, also strengthens GSK’s growing cancer portfolio. The company has been investing heavily in oncology through research, partnerships, and acquisitions, with the goal of developing more targeted treatments for different types of cancer.
Importance of Genetic Testing in Lung Cancer Treatment
Experts also stress the importance of genetic testing for lung cancer patients. Testing helps doctors identify genetic changes such as ROS1 mutations, making it easier to choose the most suitable targeted treatment for each patient.
With this FDA approval, eligible patients in the United States will soon have access to another treatment option that could help slow the progression of their disease after earlier therapies have failed. Researchers are also expected to continue studying lung cancer drug (Jideytro) to see if it can be used earlier in treatment or together with other cancer medicines.
